Antidepressant dosage form
AssigneeAlza Corporation
InventorsDavid Emil Edgren, Gurdish Kaur Bhatti, Zahedeh Hatamkhani, Patrick S.-L. Wong
Life of this patent
Estimating the term…
Abstract
A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy.
Claims3
A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an, extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
- (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;
- (b) a compartment comprising a first layer and a second layer;
- (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxypropylalkylcellulose wherein said alkyl is of 1 to 3 carbons or a hydroxyalkylcellulose wherein said alkyl is of 1 to 3 carbons;
- (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound;
- and
- (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.
A dosage form having controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
- (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;
- (b) a compartment comprising a first layer and a second layer;
- (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a poly(ethylene oxide) having a molecular weight of 100,000 to 600,000;
- (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound and a poly(ethylene oxide) comprising the repeating unit (—CH2—CH2—O—)n, wherein n is a positive whole number of 50,000 to 300,000;
- and
- (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.
A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
- (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;
- (b) a compartment comprising a first layer and a second layer;
- (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxyalkylcellulose wherein said alkyl is of 1 to 3 carbons;
- (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound;
- and
- (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.
Dependencies are inferred from the claim text.